IMPACC convalescent data collection, including Patient Reported Outcomes (PROs) and home visit sampling
IMPACC convalescent data collection, including Patient Reported Outcomes (PROs) and home visit sampling
批准号:
10205742
负责人:
OFER LEVY
金额:
$80.05万
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
已结题
起止时间:
2021-01-28 至 2023-06-30
关键词:
2019-nCoVArchitectureAwardBioinformaticsBiologicalBiological MarkersBlood specimenCOVID-19COVID-19 patientCase Report FormChinaClinicalClinical DataClinical TrialsCohort StudiesCollectionControlled Clinical TrialsCoughingCritical CareDataData AnalysesData CollectionData Coordinating CenterData Storage and RetrievalDiagnostic radiologic examinationDiseaseDisease ProgressionEnrollmentEnsureFeverGenomicsGoalsHome visitationHospitalizationHospitalsImmune responseImmunologicsImmunophenotypingInfectionInfrastructureIntegration Host FactorsInterventionInvestigationKineticsLabelLaboratoriesLung diseasesMalaiseMeasuresModelingMonitorMorbidity - disease rateMyalgiaNational Institute of Allergy and Infectious DiseaseNeonatalNewborn InfantNoseOnset of illnessParentsPatient Outcomes AssessmentsPatientsPhenotypePredispositionProcessQuality ControlReagentReportingResearchResolutionRiskSARS-CoV-2 infectionSafetySamplingSeverity of illnessSiteSystems BiologyTherapeutic AgentsTherapeutic InterventionTimeTrainingVaccinesViralViral PneumoniaVirus ReplicationVirus SheddingVisitage groupbaseclinical phenotypeclinical research sitecohortdata managementdesigndigitalevidence basefollow-upimmunogenicitymembermortalitynovel coronavirusoff-label useolder patientpandemic diseaseprimary endpointquality assurancerespiratorysafety outcomessample collectionsurveillance studytargeted treatmentvaccine accessworking group
中文摘要
点击翻译按钮获取中文摘要
英文摘要
IMmunoPhenotyping Assessment in a COVID-19 Cohort (IMPACC): Clinical and Data Coordinating
Center (CDCC)
Project summary
In December 2019, a cluster of respiratory illness in Wuhan, China defined the onset of a global pandemic
involving a novel coronavirus (SARS-CoV-2) with associated respiratory disease (COVID-19). There are major
research efforts underway to understand SARS-CoV-2 infections and the associated COVID-19 disease. The
IMmunoPhenotyping Assessment Covid-19 Cohort (IMPACC) surveillance study is based upon an observational
cohort that will collect detailed clinical, laboratory, and radiographic data in coordination with biologic sampling
of blood and respiratory secretions and viral shedding in nasal secretions. The goal of the surveillance study is
to identify immunophenotypic and genomic features of COVID-19-related susceptibility and/or progression.
The IMPACC Clinical and Data Coordinating Center (CDCC) will provide clinical and data coordination support
for the IMPACC study. This includes comprehensive study coordination and project management support across
all participating IMPACC clinical and Core laboratory sites, including initial site training and ongoing study support
through the completion of study enrollment and follow-up. The CDCC will provide clinical sites with real-time
sample tracking and data capture capabilities, including all necessary supplies and reagents for sample
collection, electronic case report forms (eCRFs) for data entry, and quality control/quality assurance (QC/QA)
processes to ensure high quality sample collection and data capture. Finally, the CDCC will design digital
infrastructure components to facilitate data management, data storage, and data analysis of study endpoint and
safety data, including interim and final analysis of primary endpoints, ongoing safety and outcome monitoring,
and bioinformatics analytic support for secondary/exploratory endpoints.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Immune development in early life (IDEAL) shapes vaccine response, respiratory infectious diseaseand asthma
-
批准号:10435035
-
项目类别:
-
资助金额:$166.59万
-
财政年份:2022
-
负责人:OFER LEVY
-
依托单位:
Project 3: In vitro modeling to define mechanisms of childhood vaccine response, susceptibility to respiratory infectious disease and asthma
-
批准号:10589826
-
项目类别:
-
资助金额:$22.79万
-
财政年份:2022
-
负责人:OFER LEVY
-
依托单位:
Project 3: In vitro modeling to define mechanisms of childhood vaccine response, susceptibility to respiratory infectious disease and asthma
-
批准号:10435043
-
项目类别:
-
资助金额:$19.86万
-
财政年份:2022
-
负责人:OFER LEVY
-
依托单位:
Immune development in early life (IDEAL) shapes vaccine response, respiratory infectious diseaseand asthma
-
批准号:10589800
-
项目类别:
-
资助金额:$154.65万
-
财政年份:2022
-
负责人:OFER LEVY
-
依托单位:
Administrative Core: IDEAL shapes vaccine response, susceptibility to respiratory infectious disease and asthma
-
批准号:10435036
-
项目类别:
-
资助金额:$12.39万
-
财政年份:2022
-
负责人:OFER LEVY
-
依托单位:
Administrative Core: IDEAL shapes vaccine response, susceptibility to respiratory infectious disease and asthma
-
批准号:10589801
-
项目类别:
-
资助金额:$11.18万
-
财政年份:2022
-
负责人:OFER LEVY
-
依托单位:
IMPACC convalescent data collection, including Patient Reported Outcomes (PROs) and home visit sampling
-
批准号:10290547
-
项目类别:
-
资助金额:$212.99万
-
财政年份:2021
-
负责人:OFER LEVY
-
依托单位:
Newborn cohorts to discover and validate biomarkers of neonatal vaccine immunogenicity
-
批准号:10323182
-
项目类别:
-
资助金额:$16.15万
-
财政年份:2020
-
负责人:OFER LEVY
-
依托单位:
Systems Biology to Identify Biomarkers of Neonatal Vaccine Immunogenicity
-
批准号:10221106
-
项目类别:
-
资助金额:$11.11万
-
财政年份:2020
-
负责人:OFER LEVY
-
依托单位:
Systems Biology to Identify Biomarkers of Neonatal Vaccine Immunogenicity
-
批准号:10265669
-
项目类别:
-
资助金额:$210.3万
-
财政年份:2020
-
负责人:OFER LEVY
-
依托单位:
In vitro modeling to characterize mechanisms of neonatal vaccine induced immune responses
-
批准号:10323193
-
项目类别:
-
资助金额:$85.52万
-
财政年份:2020
-
负责人:OFER LEVY
-
依托单位:
Clinical and Data Coordinating Center (CDCC)]
-
批准号:10323176
-
项目类别:
-
资助金额:$210.3万
-
财政年份:2020
-
负责人:OFER LEVY
-
依托单位:
Systems Biology to Identify Biomarkers of Neonatal Vaccine Immunogenicity
-
批准号:10265671
-
项目类别:
-
资助金额:$16.15万
-
财政年份:2020
-
负责人:OFER LEVY
-
依托单位:
Systems Biology to Identify Biomarkers of Neonatal Vaccine Immunogenicity
-
批准号:10265673
-
项目类别:
-
资助金额:$85.52万
-
财政年份:2020
-
负责人:OFER LEVY
-
依托单位:
Systems Biology to Identify Biomarkers of Neonatal Vaccine Immunogenicity
-
批准号:10265672
-
项目类别:
-
资助金额:$227.57万
-
财政年份:2020
-
负责人:OFER LEVY
-
依托单位:
Adjuvant testing pipeline for recombinant SARS-CoV2 vaccines
-
批准号:10473587
-
项目类别:
-
资助金额:$25.7万
-
财政年份:2019
-
负责人:OFER LEVY
-
依托单位:
Small-molecule adjuvants testing pipeline (Influenza)
-
批准号:10834716
-
项目类别:
-
资助金额:$139.21万
-
财政年份:2019
-
负责人:OFER LEVY
-
依托单位:
Small-molecule adjuvants to enhance the efficacy of flu vaccines in newborns and the elderly
-
批准号:10027076
-
项目类别:
-
资助金额:$172.29万
-
财政年份:2019
-
负责人:OFER LEVY
-
依托单位:
Adjuvant testing pipeline for recombinant SARS-CoV2 vaccines
-
批准号:10301484
-
项目类别:
-
资助金额:$179.03万
-
财政年份:2019
-
负责人:OFER LEVY
-
依托单位:
Small-molecule adjuvants testing pipeline (Influenza)
-
批准号:10641647
-
项目类别:
-
资助金额:$212.73万
-
财政年份:2019
-
负责人:OFER LEVY
-
依托单位:
海外基金